Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vinayak Venkataraman

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
JAMA|January 5, 2024
Setting IntentionsVinayak Venkataraman
Proceedings (Baylor University. Medical Center)|October 26, 2020
Irritable bowel syndrome leading to scurvy from a severely restricted dietVinayak Venkataraman, Kristian R Olson
The Oncologist|June 14, 2023
Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal TumorVinayak Venkataraman, Suzanne George, Gregory M Cote
Hematology. American Society of Hematology. Education Program|December 10, 2021
Blast and accelerated phase CML: room for improvementJoan How, Vinayak Venkataraman, Gabriela Soriano Hobbs
Research and Practice in Thrombosis and Haemostasis|July 23, 2024
Hyperfibrinolysis during the treatment of rhabdomyosarcomaSamuel R Taylor, Jean M Connors, Vinayak Venkataraman
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 2, 2022
Incidence of bleeding events in patients on concomitant tyrosine kinase inhibitors and selective serotonin reuptake inhibitorsVinayak Venkataraman, John R Bales, Jessie Signorelli, et al.
Clinical and Translational Science|September 5, 2014
Impact of alternative medical device approval processes on costs and healthBenjamin P George, Vinayak Venkataraman, E Ray Dorsey, et al.
Pediatric Blood & Cancer|June 1, 2021
Secondary histiocytic sarcoma with BRAF<sup>V600E</sup> mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapyVinayak Venkataraman, Lucas R Massoth, Ryan J Sullivan, et al.
Pediatric Blood & Cancer|February 11, 2020
Secondary histiocytic sarcoma with BRAF<sup>V600E</sup> mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinibVinayak Venkataraman, Lucas R Massoth, Ryan J Sullivan, et al.
JAMA Neurology|March 3, 2015
Novel methods and technologies for 21st-century clinical trials: a reviewE Ray Dorsey, Charles Venuto, Vinayak Venkataraman, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
JAMA|January 5, 2024
Setting IntentionsVinayak Venkataraman
Proceedings (Baylor University. Medical Center)|October 26, 2020
Irritable bowel syndrome leading to scurvy from a severely restricted dietVinayak Venkataraman, Kristian R Olson
The Oncologist|June 14, 2023
Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal TumorVinayak Venkataraman, Suzanne George, Gregory M Cote
Hematology. American Society of Hematology. Education Program|December 10, 2021
Blast and accelerated phase CML: room for improvementJoan How, Vinayak Venkataraman, Gabriela Soriano Hobbs
Research and Practice in Thrombosis and Haemostasis|July 23, 2024
Hyperfibrinolysis during the treatment of rhabdomyosarcomaSamuel R Taylor, Jean M Connors, Vinayak Venkataraman
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 2, 2022
Incidence of bleeding events in patients on concomitant tyrosine kinase inhibitors and selective serotonin reuptake inhibitorsVinayak Venkataraman, John R Bales, Jessie Signorelli, et al.
Clinical and Translational Science|September 5, 2014
Impact of alternative medical device approval processes on costs and healthBenjamin P George, Vinayak Venkataraman, E Ray Dorsey, et al.
Pediatric Blood & Cancer|June 1, 2021
Secondary histiocytic sarcoma with BRAF<sup>V600E</sup> mutation responsive to MAPK-targeted therapy presenting with recurrence with mTOR mutation responsive to mTOR-targeted therapyVinayak Venkataraman, Lucas R Massoth, Ryan J Sullivan, et al.
Pediatric Blood & Cancer|February 11, 2020
Secondary histiocytic sarcoma with BRAF<sup>V600E</sup> mutation after T-cell acute lymphoblastic leukemia in a very young child with dramatic response to dabrafenib and trametinibVinayak Venkataraman, Lucas R Massoth, Ryan J Sullivan, et al.
JAMA Neurology|March 3, 2015
Novel methods and technologies for 21st-century clinical trials: a reviewE Ray Dorsey, Charles Venuto, Vinayak Venkataraman, et al.
Pageof 3